Cart
sales@molnova.com
Chromeceptin
CAS No. 331859-86-0
Chromeceptin( 2-amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile )
Catalog No. M28518 CAS No. 331859-86-0
Chromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | Get Quote |
|
| 5MG | 65 | Get Quote |
|
| 10MG | 102 | Get Quote |
|
| 25MG | 215 | Get Quote |
|
| 50MG | 312 | Get Quote |
|
| 100MG | 484 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameChromeceptin
-
NoteResearch use only, not for human use.
-
Brief DescriptionChromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.
-
DescriptionChromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.(In Vitro):In Hep3B-derived TS cells, Chromeceptin (5 μM) inhibits IGF2 expression in a time-dependent manner. Chromeceptin suppresses IGF-2 expression at mRNA and protein levels in HCC cells.
-
In Vitro——
-
In Vivo——
-
Synonyms2-amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetAkt
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number331859-86-0
-
Formula Weight359.35
-
Molecular FormulaC19H16F3N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (278.28 mM)
-
SMILESN#CC1=C(OC2=CC(=CC=C2C1C3=CC=CC(=C3)C(F)(F)F)N(C)C)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Lenaldekar
Lenaldekar inhibits T-cell expansion and autoimmune encephalomyelitis.
-
AT7867 dihydrochlori...
AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM.
-
Actein
Actein has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis, it also can prevent oxidative damage to osteoblasts in osteoporotic patients.
